Protocol for measuring in vivo, ex vivo, and in vitro glucose uptake in brown adipocytes Authors: Chul-Hong Park, Ji Suk Chang Published: 2025 ABSTRACT SummaryHere, we present a protocol for assessing in vivo glucose uptake in brown adipose tissue (BAT) from mice using 2-deoxy-D-[1,2=-3H]glucose. We describe steps for reagent and animal preparation, tracer administration, and tissue processing to quantify radiolabeled glucose uptake and its conversion to glucose-6-phosphate. We then detail procedures for conducting glucose uptake assays in freshly isolated BAT and cultured brown adipocytes, enabling assessment under a range of experimental conditions.For complete details on the use and execution of this protocol, please refer to Park et al.1Subject areas: cell-based assays, Health Sciences, Metabolism Before you begin Innovation 2-deoxy-D-glucose (2DG) is a non-metabolizable glucose analog that closely resembles glucose structurally but lacks the hydroxyl group at the 2-position, rendering it incapable of progressing beyond the initial phosphorylation step catalyzed by hexokinase in glycolysis.2 This leads to intracellular accumulation of 2-deoxy-D-glucose-6-phosphate (2DG6P), providing a reliable proxy for quantifying glucose transport activity. Leveraging this property, we present a comprehensive protocol for assessing β-adrenergic stimulated glucose uptake in brown adipose tissue using radiolabeled 2-deoxy-D-[1,2-3H]glucose. This protocol details procedures for in vivo tracer administration, tissue harvesting, and quantification of radiolabeled glucose uptake and utilization. In addition, it includes adaptations for ex vivo and in vitro glucose uptake assays in brown adipocytes, enabling versatile application across experimental models and conditions. Institutional permissions Institutional Animal Care and Use Committee approval must be obtained prior to initiating any animal experiments. This study was carried out in accordance with the institutional guidelines and were approved by the Institutional Animal Care and Use Committee of the Pennington Biomedical Research Center (protocol number #IACUCPB-22-011). All mice were housed in a temperature-controlled (22°C–23°C) room under a 12-h light/12-h dark cycle with ad libitum access to food and water. 10-to-19-week-old male and female mice were used for animal experiments. In addition, institutional approval for the use of radioactive materials must be obtained prior to the purchase and use of 2-deoxy-D-[1,2-3H]glucose as described in this protocol. Preparation of mice for in vivo and ex vivo glucose uptake assays Timing: 1 day 1.Randomly assign 8–10 mice to each experimental group and transfer them to new clean cages in groups (2 animals per cage). Refer to troubleshooting 1. Randomly assign 8–10 mice to each experimental group and transfer them to new clean cages in groups (2 animals per cage). Refer to troubleshooting 1. Note: Metabolic phenotypes are influenced by multiple factors, including mouse strain, age, sex, diet, and housing conditions such as ambient temperature. To ensure valid comparisons, these variables should be carefully matched across all experimental groups. 2.Remove food while allowing free access to water. Remove food while allowing free access to water. Note: Fasting reduces baseline glucose and insulin levels, improving sensitivity to changes. Fasting duration ranging from 5 h to overnight (approximately 12–16 h) are routinely used prior to 2-deoxy-D-[1,2-3H]glucose uptake assays and glucose tolerance tests. However, short-term fasting (5–6 h) is generally preferred to minimize physiological stress and maintain metabolic relevance. The optimal fasting duration may vary depending on the experimental objectives, dietary conditions, and the route of glucose administration. It should be carefully determined to balance physiological relevance, minimize stress, and ensure data consistency. Note: For the ex vivo glucose uptake assay, fasting is not required. 3.Weigh each mouse individually to calculate the injection volume of 2-deoxy-D-[1,2-3H]glucose solution, as well as the β3-adrenergic receptor agonist CL316243, if used to stimulate brown adipose tissue (BAT). CL316243 is well established to activate BAT, enhancing thermogenesis and glucose uptake in BAT.3,4,5 Weigh each mouse individually to calculate the injection volume of 2-deoxy-D-[1,2-3H]glucose solution, as well as the β3-adrenergic receptor agonist CL316243, if used to stimulate brown adipose tissue (BAT). CL316243 is well established to activate BAT, enhancing thermogenesis and glucose uptake in BAT.3,4,5 Note: Alternatively, mice can be exposed to cold temperature (4°C–6°C) to activate BAT if a temperature-controlled housing chamber is available. Preparation of brown adipocytes for in vitro glucose uptake assay Timing: 11–12 days 4.Seed brown preadipocytes at a density of 3 × 104 cells per well (approximately 30% confluence) in a 12-well plate using pre-warmed culture medium. Seed brown preadipocytes at a density of 3 × 104 cells per well (approximately 30% confluence) in a 12-well plate using pre-warmed culture medium. Note: Brown preadipocytes can be isolated from neonatal pups up to 4 days of age. For complete details of the brown preadipocyte isolation and differentiation protocol, please refer to Fasshauer et al.6 and Fasshauer et al.7 5.Allow the cells to grow in a 37°C cell culture incubator for approximately 2 to 2 ½ days or until they reach 90%–100% confluence. Allow the cells to grow in a 37°C cell culture incubator for approximately 2 to 2 ½ days or until they reach 90%–100% confluence. CRITICAL: Even distribution is the most critical factor for achieving 100% differentiation efficiency. Refer to troubleshooting 2. 6.Once cells reach 90%–100% confluence, induce differentiation by replacing the culture medium with the induction medium supplemented with 20 nM insulin, 1 nM T3, 5 μM dexamethasone, 0.125 mM indomethacin, and 0.5 mM IBMX. Incubate the cells at 37°C for 2 days. Once cells reach 90%–100% confluence, induce differentiation by replacing the culture medium with the induction medium supplemented with 20 nM insulin, 1 nM T3, 5 μM dexamethasone, 0.125 mM indomethacin, and 0.5 mM IBMX. Incubate the cells at 37°C for 2 days. 7.After the 2-day induction period, replace the medium with differentiation medium containing 20 nM insulin and 1 nM T3. Incubate the cells at 37°C. After the 2-day induction period, replace the medium with differentiation medium containing 20 nM insulin and 1 nM T3. Incubate the cells at 37°C. 8.Change the medium every 2 days for an additional 5 days, or until the cells are fully differentiated. Change the medium every 2 days for an additional 5 days, or until the cells are fully differentiated. Note: To assess the effect of β-adrenergic activation on glucose uptake in brown adipocytes, treat the cells with the β-adrenergic receptor agonist isoproterenol at a final concentration of 5 μM for 4 h prior to conducting the glucose uptake assay. Key resources table REAGENT or RESOURCESOURCEIDENTIFIERChemicals, peptides, and recombinant proteins2-deoxy-D-[1,2–3H] glucosePerkinElmerCat# NET328A2-deoxy-D-glucose (2-DG)Sigma-AldrichCat# D-8375CL316243 disodium saltTocrisCat# 1499Sodium hydroxideThermo Fisher ScientificCat# S318-500Hydrochloric acid standard solutionFlukaCat# 7182670% Perchloric acidSigma-AldrichCat# 311421Barium hydroxide solutionSigma-AldrichCat# B-4059Zinc sulfate heptahydrateSigma-AldrichCat# Z-0251Sodium chlorideFisher ScientificCat# S271-500Potassium chlorideFisher ScientificCat# P333-500Potassium phosphate monobasicFisher ScientificCat# P386-500Magnesium sulfateSigmaCat# M2643Sodium bicarbonateFisher ScientificCat# S233-500Calcium chlorideFisher ScientificCat# C69-500HEPES (1 M)Thermo Fisher ScientificCat# 15-630-080Albumin bovine fraction V fatty acid freeMP BiomedicalsCat# 152401Cytochalasin BSigma-AldrichCat# C-6762DMEM, high glucose, pyruvate, no glutamineThermo Fisher ScientificCat# 10-313-039DMEM, no glucose, no glutamine, no phenol redThermo Fisher ScientificCat# A1443001FBSCytivaCat# SH30396.03Penicillin-Streptomycin (10,000 U/mL)Thermo Fisher ScientificCat# 15-140-122L-Glutamine (200 mM)Thermo Fisher ScientificCat# 25-030-081D-(+)-GlucoseSigma-AldrichCat# G-6152Sodium pyruvateSigma-AldrichCat# P-2256Insulin from bovine pancreasSigma-AldrichCat# I-5500T3Sigma-AldrichCat# T-28773-Isobutyl-1-methylxanthine (IBMX)Sigma-AldrichCat# I-5879DexamethasoneSigma-AldrichCat# D-1756IndomethacinSigma-AldrichCat# I-7378UNISCINT BD 4 LTNational DiagnosticsCat# LS-276Critical commercial assaysBCA Protein Assay KitsThermo Fisher ScientificCat# 23225Experimental models: Organisms/strainsC57BL/6 mice, both of sex, 12–14 weeks of ageIn-house colonyN/AR26-Got1 knockin female mice, 12–14 weeks of agePark et al.1N/ASoftware and algorithmsPrism 10 softwareGraphPad Software, Inc.SCR_002798Graphic abstract and schematics in figureshttps://www.biorender.comN/AOther12-well platesCorning costarCat# CLS3512Syringe filter, 0.22 μmCELLTREAT ScientificCat# CLS3512Safe-Lock Tubes, 1.5 mL - MicrotubesEppendorfCat# 02236320414 mL round bottom polystyrene test tubesCorningCat# 352001Scintillation vialsVWRCat# 66022-300High precision analytical balanceMettler ToledoAB54-SShaking water bathAmerican ScientificYB-531Heat blockFisher Scientific11-718-8pH meterOaktonpH 510Refrigerated microcentrifugeEppendorf5417RCell culture incubatorSanyoMCO-20AICSpectraMax Plus 384 Absorbance Plate ReaderMolecular DevicesSCR_018598Tri-Carb 2910TR liquid scintillation analyzerPerkinElmerN/A Materials and equipment 2-deoxy-D-[1,2-3H]glucose solution for in vivo glucose uptake assayReagentFinal concentrationAmount2-deoxy-D-[1,2-3H]glucose (1 mCi/mL)100 μCi/mL100 μL20% glucose (0.2 g/mL)20%900 μLTotal1000 μL 2-deoxy-D-[1,2-3H]glucose solution for in vivo glucose uptake assay Note: For 25 g of a mouse, administer 125 μL (25 g × 5 μL/g) to achieve a final concentration of 0.5 μCi/g BW of 2-deoxy-D-[1,2-3H]glucose and 1 mg/g BW of glucose. Prepare this solution immediately prior to use. 2-deoxy-D-[1,2-3H]glucose solution for ex vivo glucose uptake assayReagentStock concentrationWorking concentration (100×)Final concentration (1×)Amount for 100× solution2-deoxy-D-[1,2-3H]glucose1 mCi/mL100 μCi/mL1 μCi/mL10 μL2-deoxy-D-glucose100 mM20 mM0.2 mM20 μLGlucose-free KRBB bufferN/AN/AN/A70 μLTotal100 μL 2-deoxy-D-[1,2-3H]glucose solution for ex vivo glucose uptake assay Note: Add 10 μL of a 100× working solution to 1 mL of tissue sample in a 14 mL tube. Prepare this solution immediately prior to use. 2-deoxy-D-[1,2-3H]glucose solution for in vitro glucose uptake assayReagentStock concentrationFinal concentrationAmount2-deoxy-D-[1,2–3H] glucose1 mCi/mL1 μCi/mL6 μL2-deoxy-D-glucose100 mM0.2 mM12 μLBSA10%1 %600 μLL-glutamine200 mM2 mM60 μLSodium Pyruvate100 mM1 mM60 μLGlucose-free DMEMN/AN/A5,262 μLTotal6,000 μL 2-deoxy-D-[1,2-3H]glucose solution for in vitro glucose uptake assay Note: For a 12-well plate, add 500 μL per well. Prepare this solution immediately prior to use. Culture mediumReagentStock concentrationFinal concentrationAmountDMEMN/AN/A440 mLFBS100 %10 %50 mLL-glutamine200 mM2 mM5 mLPen/Strep100×1×5 mLTotal500 mL Culture medium Note: Filter sterilize using a 0.22 μm filter before use and store at 4°C for several weeks. Induction mediumReagentStock concentrationFinal concentrationAmountInsulin20 μM in 0.02 N HCl20 nM25 μLT31 μM in 0.2 N NaOH1 nM25 μLDexamethasone5 mM in ethanol5 μM25 μLIndomethacin62.5 mM in ethanol0.125 mM50 μLIBMX75 mM in ethanol0.5 mM167 μLCMN/AN/A24,708 μLTotal25,000 μL Induction medium Note: Filter sterilize using a 0.22 μm filter and use immediately. For a 12-well plate, add 2 mL per well. Differentiation mediumReagentStock concentrationFinal concentrationAmountInsulin20 μM in 0.02 N HCl20 nM25 μLT31 μM in 0.2 N NaOH1 nM25 μLDMEM culture mediaN/AN/A24,950 μLTotal25,000 μL Differentiation medium Note: Filter sterilize using a 0.22 μm filter and use immediately. For a 12-well plate, add 2 mL per well. Step-by-step method details In vivo tissue-specific glucose uptake assay Timing: 5 h This in vivo glucose uptake protocol is a close adaptation of protocols described in Ferre et al.8 and Moller et al.9 which utilize radiolabeled 2-deoxy-D-[1,2-3H]glucose to assess tissue-specific glucose uptake. This section describes the preparation of the 2-deoxy-D-[1,2-3H]glucose solution, its administration to mice with or without the β3-adrenergic receptor agonist CL316243, and subsequent tissue processing to quantify 2-deoxy-D-[1,2-3H]glucose uptake across various tissues. 1.Preparation of 2-deoxy-D-[1,2-3H]glucose solution and other reagents.a.Prepare 2-deoxy-D-[1,2-3H]glucose ([3H]-2DG) working solution.i.To administer a dose of 0.5 μCi per gram body weight using a [3H]-2DG working solution at 100 μCi/mL, calculate the injection volume (in μL) for each mouse by multiplying its body weight (in grams) by 5 μL.Note: For example, ten mice weighing 25 g each would require a total volume of 1,250 μL (10 × 25 g × 5 μL/g) for the experiment.ii.Add [3H]-2DG (stock radioactivity: 1 mCi/mL) to 20% glucose solution in a volume ratio of 1:10 to generate a final concentration of 100 μCi/mL.Note: Be sure to prepare extra volume beyond the calculated amount to account for any potential loss or error during handling.Note: Dissolving [3H]-2DG in 20% glucose ensures that its uptake occurs through glucose-specific transport mechanisms.Note: The administrated dose of [3H]-2DG can be adjusted based on the specific tissue of interest.CRITICAL: Personal protective equipment (PPE) must be worn while handling radioactive materials. Radioactive experiments must be carried out in the designated area.b.Prepare a solution of the β3-adrenergic receptor agonist CL316243.i.To administer a dose of 1 μg per gram body weight using a CL316243 solution at 0.2 mg/mL, calculate the injection volume (in μL) for each mouse by multiplying its body weight (in grams) by 5 μL.Note: For example, ten mice weighing 25 g each would require a total volume of 1,250 μL (10 × 25 g × 5 μL/g) for the experiment.ii.Dissolve 5 mg of CL316243 in 5 mL water to a final concentration of 1 mg/mL, filter sterilize the stock solution using a 0.22 μm filter, and then aliquot and store in −80°C freezer.iii.Dilute CL316243 stock solution in sterile saline to generate a final concentration of 0.2 mg/mL.Note: Be sure to prepare extra volume beyond the calculated amount to account for any potential loss or error during handling.Note: The β3-adrenergic receptor agonist CL316243 selectively activates β3-adrenergic receptors enriched in brown and white adipose tissue.3,4,5 Preparation of 2-deoxy-D-[1,2-3H]glucose solution and other reagents.a.Prepare 2-deoxy-D-[1,2-3H]glucose ([3H]-2DG) working solution.i.To administer a dose of 0.5 μCi per gram body weight using a [3H]-2DG working solution at 100 μCi/mL, calculate the injection volume (in μL) for each mouse by multiplying its body weight (in grams) by 5 μL.Note: For example, ten mice weighing 25 g each would require a total volume of 1,250 μL (10 × 25 g × 5 μL/g) for the experiment.ii.Add [3H]-2DG (stock radioactivity: 1 mCi/mL) to 20% glucose solution in a volume ratio of 1:10 to generate a final concentration of 100 μCi/mL.Note: Be sure to prepare extra volume beyond the calculated amount to account for any potential loss or error during handling.Note: Dissolving [3H]-2DG in 20% glucose ensures that its uptake occurs through glucose-specific transport mechanisms.Note: The administrated dose of [3H]-2DG can be adjusted based on the specific tissue of interest.CRITICAL: Personal protective equipment (PPE) must be worn while handling radioactive materials. Radioactive experiments must be carried out in the designated area.b.Prepare a solution of the β3-adrenergic receptor agonist CL316243.i.To administer a dose of 1 μg per gram body weight using a CL316243 solution at 0.2 mg/mL, calculate the injection volume (in μL) for each mouse by multiplying its body weight (in grams) by 5 μL.Note: For example, ten mice weighing 25 g each would require a total volume of 1,250 μL (10 × 25 g × 5 μL/g) for the experiment.ii.Dissolve 5 mg of CL316243 in 5 mL water to a final concentration of 1 mg/mL, filter sterilize the stock solution using a 0.22 μm filter, and then aliquot and store in −80°C freezer.iii.Dilute CL316243 stock solution in sterile saline to generate a final concentration of 0.2 mg/mL.Note: Be sure to prepare extra volume beyond the calculated amount to account for any potential loss or error during handling.Note: The β3-adrenergic receptor agonist CL316243 selectively activates β3-adrenergic receptors enriched in brown and white adipose tissue.3,4,5 a.Prepare 2-deoxy-D-[1,2-3H]glucose ([3H]-2DG) working solution.i.To administer a dose of 0.5 μCi per gram body weight using a [3H]-2DG working solution at 100 μCi/mL, calculate the injection volume (in μL) for each mouse by multiplying its body weight (in grams) by 5 μL.Note: For example, ten mice weighing 25 g each would require a total volume of 1,250 μL (10 × 25 g × 5 μL/g) for the experiment.ii.Add [3H]-2DG (stock radioactivity: 1 mCi/mL) to 20% glucose solution in a volume ratio of 1:10 to generate a final concentration of 100 μCi/mL.Note: Be sure to prepare extra volume beyond the calculated amount to account for any potential loss or error during handling.Note: Dissolving [3H]-2DG in 20% glucose ensures that its uptake occurs through glucose-specific transport mechanisms.Note: The administrated dose of [3H]-2DG can be adjusted based on the specific tissue of interest.CRITICAL: Personal protective equipment (PPE) must be worn while handling radioactive materials. Radioactive experiments must be carried out in the designated area. Prepare 2-deoxy-D-[1,2-3H]glucose ([3H]-2DG) working solution.i.To administer a dose of 0.5 μCi per gram body weight using a [3H]-2DG working solution at 100 μCi/mL, calculate the injection volume (in μL) for each mouse by multiplying its body weight (in grams) by 5 μL.Note: For example, ten mice weighing 25 g each would require a total volume of 1,250 μL (10 × 25 g × 5 μL/g) for the experiment.ii.Add [3H]-2DG (stock radioactivity: 1 mCi/mL) to 20% glucose solution in a volume ratio of 1:10 to generate a final concentration of 100 μCi/mL.Note: Be sure to prepare extra volume beyond the calculated amount to account for any potential loss or error during handling.Note: Dissolving [3H]-2DG in 20% glucose ensures that its uptake occurs through glucose-specific transport mechanisms.Note: The administrated dose of [3H]-2DG can be adjusted based on the specific tissue of interest.CRITICAL: Personal protective equipment (PPE) must be worn while handling radioactive materials. Radioactive experiments must be carried out in the designated area. i.To administer a dose of 0.5 μCi per gram body weight using a [3H]-2DG working solution at 100 μCi/mL, calculate the injection volume (in μL) for each mouse by multiplying its body weight (in grams) by 5 μL.Note: For example, ten mice weighing 25 g each would require a total volume of 1,250 μL (10 × 25 g × 5 μL/g) for the experiment. To administer a dose of 0.5 μCi per gram body weight using a [3H]-2DG working solution at 100 μCi/mL, calculate the injection volume (in μL) for each mouse by multiplying its body weight (in grams) by 5 μL.Note: For example, ten mice weighing 25 g each would require a total volume of 1,250 μL (10 × 25 g × 5 μL/g) for the experiment. Note: For example, ten mice weighing 25 g each would require a total volume of 1,250 μL (10 × 25 g × 5 μL/g) for the experiment. ii.Add [3H]-2DG (stock radioactivity: 1 mCi/mL) to 20% glucose solution in a volume ratio of 1:10 to generate a final concentration of 100 μCi/mL.Note: Be sure to prepare extra volume beyond the calculated amount to account for any potential loss or error during handling.Note: Dissolving [3H]-2DG in 20% glucose ensures that its uptake occurs through glucose-specific transport mechanisms.Note: The administrated dose of [3H]-2DG can be adjusted based on the specific tissue of interest.CRITICAL: Personal protective equipment (PPE) must be worn while handling radioactive materials. Radioactive experiments must be carried out in the designated area. Add [3H]-2DG (stock radioactivity: 1 mCi/mL) to 20% glucose solution in a volume ratio of 1:10 to generate a final concentration of 100 μCi/mL.Note: Be sure to prepare extra volume beyond the calculated amount to account for any potential loss or error during handling.Note: Dissolving [3H]-2DG in 20% glucose ensures that its uptake occurs through glucose-specific transport mechanisms.Note: The administrated dose of [3H]-2DG can be adjusted based on the specific tissue of interest.CRITICAL: Personal protective equipment (PPE) must be worn while handling radioactive materials. Radioactive experiments must be carried out in the designated area. Note: Be sure to prepare extra volume beyond the calculated amount to account for any potential loss or error during handling. Note: Dissolving [3H]-2DG in 20% glucose ensures that its uptake occurs through glucose-specific transport mechanisms. Note: The administrated dose of [3H]-2DG can be adjusted based on the specific tissue of interest. CRITICAL: Personal protective equipment (PPE) must be worn while handling radioactive materials. Radioactive experiments must be carried out in the designated area. b.Prepare a solution of the β3-adrenergic receptor agonist CL316243.i.To administer a dose of 1 μg per gram body weight using a CL316243 solution at 0.2 mg/mL, calculate the injection volume (in μL) for each mouse by multiplying its body weight (in grams) by 5 μL.Note: For example, ten mice weighing 25 g each would require a total volume of 1,250 μL (10 × 25 g × 5 μL/g) for the experiment.ii.Dissolve 5 mg of CL316243 in 5 mL water to a final concentration of 1 mg/mL, filter sterilize the stock solution using a 0.22 μm filter, and then aliquot and store in −80°C freezer.iii.Dilute CL316243 stock solution in sterile saline to generate a final concentration of 0.2 mg/mL.Note: Be sure to prepare extra volume beyond the calculated amount to account for any potential loss or error during handling.Note: The β3-adrenergic receptor agonist CL316243 selectively activates β3-adrenergic receptors enriched in brown and white adipose tissue.3,4,5 Prepare a solution of the β3-adrenergic receptor agonist CL316243.i.To administer a dose of 1 μg per gram body weight using a CL316243 solution at 0.2 mg/mL, calculate the injection volume (in μL) for each mouse by multiplying its body weight (in grams) by 5 μL.Note: For example, ten mice weighing 25 g each would require a total volume of 1,250 μL (10 × 25 g × 5 μL/g) for the experiment.ii.Dissolve 5 mg of CL316243 in 5 mL water to a final concentration of 1 mg/mL, filter sterilize the stock solution using a 0.22 μm filter, and then aliquot and store in −80°C freezer.iii.Dilute CL316243 stock solution in sterile saline to generate a final concentration of 0.2 mg/mL.Note: Be sure to prepare extra volume beyond the calculated amount to account for any potential loss or error during handling.Note: The β3-adrenergic receptor agonist CL316243 selectively activates β3-adrenergic receptors enriched in brown and white adipose tissue.3,4,5 i.To administer a dose of 1 μg per gram body weight using a CL316243 solution at 0.2 mg/mL, calculate the injection volume (in μL) for each mouse by multiplying its body weight (in grams) by 5 μL.Note: For example, ten mice weighing 25 g each would require a total volume of 1,250 μL (10 × 25 g × 5 μL/g) for the experiment. To administer a dose of 1 μg per gram body weight using a CL316243 solution at 0.2 mg/mL, calculate the injection volume (in μL) for each mouse by multiplying its body weight (in grams) by 5 μL.Note: For example, ten mice weighing 25 g each would require a total volume of 1,250 μL (10 × 25 g × 5 μL/g) for the experiment. Note: For example, ten mice weighing 25 g each would require a total volume of 1,250 μL (10 × 25 g × 5 μL/g) for the experiment. ii.Dissolve 5 mg of CL316243 in 5 mL water to a final concentration of 1 mg/mL, filter sterilize the stock solution using a 0.22 μm filter, and then aliquot and store in −80°C freezer. Dissolve 5 mg of CL316243 in 5 mL water to a final concentration of 1 mg/mL, filter sterilize the stock solution using a 0.22 μm filter, and then aliquot and store in −80°C freezer. iii.Dilute CL316243 stock solution in sterile saline to generate a final concentration of 0.2 mg/mL.Note: Be sure to prepare extra volume beyond the calculated amount to account for any potential loss or error during handling.Note: The β3-adrenergic receptor agonist CL316243 selectively activates β3-adrenergic receptors enriched in brown and white adipose tissue.3,4,5 Dilute CL316243 stock solution in sterile saline to generate a final concentration of 0.2 mg/mL.Note: Be sure to prepare extra volume beyond the calculated amount to account for any potential loss or error during handling.Note: The β3-adrenergic receptor agonist CL316243 selectively activates β3-adrenergic receptors enriched in brown and white adipose tissue.3,4,5 Note: Be sure to prepare extra volume beyond the calculated amount to account for any potential loss or error during handling. Note: The β3-adrenergic receptor agonist CL316243 selectively activates β3-adrenergic receptors enriched in brown and white adipose tissue.3,4,5 2.Administration of 2-deoxy-D-[1,2-3H]glucose into mice followed by tissue harvesting.a.Administer the [3H]-2DG solution via intraperitoneal (IP) injection at a dose of 0.5 μCi per gram body weight, using the calculated volume for each mouse.Note: To activate brown and white adipose tissue, administer the CL316243 solution by IP injection at a dose of 1 μg per gram body weight 15 min prior to the [3H]-2DG injection.Note: Alternatively, intravenous (IV) injection may be considered to reduce potential intra-group variability, which can result from inconsistencies in absorption or distribution associated with IP administration.b.45 min after [3H]-2DG administration, euthanize the mouse and dissect tissues, including brown adipose tissue (BAT), inguinal white adipose tissue (iWAT), gonadal white adipose tissue (gWAT), skeletal muscle, kidney, heart, lung, and liver.Note: Stagger the injections by 15-min intervals to ensure that all mice are scarified at the same time point following [3H]-2DG administration (see Table 1). It is recommended that one person performs the injections while another person handles the sacrifices and tissue collections 45 min post-injection. Administration of 2-deoxy-D-[1,2-3H]glucose into mice followed by tissue harvesting.a.Administer the [3H]-2DG solution via intraperitoneal (IP) injection at a dose of 0.5 μCi per gram body weight, using the calculated volume for each mouse.Note: To activate brown and white adipose tissue, administer the CL316243 solution by IP injection at a dose of 1 μg per gram body weight 15 min prior to the [3H]-2DG injection.Note: Alternatively, intravenous (IV) injection may be considered to reduce potential intra-group variability, which can result from inconsistencies in absorption or distribution associated with IP administration.b.45 min after [3H]-2DG administration, euthanize the mouse and dissect tissues, including brown adipose tissue (BAT), inguinal white adipose tissue (iWAT), gonadal white adipose tissue (gWAT), skeletal muscle, kidney, heart, lung, and liver.Note: Stagger the injections by 15-min intervals to ensure that all mice are scarified at the same time point following [3H]-2DG administration (see Table 1). It is recommended that one person performs the injections while another person handles the sacrifices and tissue collections 45 min post-injection. a.Administer the [3H]-2DG solution via intraperitoneal (IP) injection at a dose of 0.5 μCi per gram body weight, using the calculated volume for each mouse.Note: To activate brown and white adipose tissue, administer the CL316243 solution by IP injection at a dose of 1 μg per gram body weight 15 min prior to the [3H]-2DG injection.Note: Alternatively, intravenous (IV) injection may be considered to reduce potential intra-group variability, which can result from inconsistencies in absorption or distribution associated with IP administration. Administer the [3H]-2DG solution via intraperitoneal (IP) injection at a dose of 0.5 μCi per gram body weight, using the calculated volume for each mouse.Note: To activate brown and white adipose tissue, administer the CL316243 solution by IP injection at a dose of 1 μg per gram body weight 15 min prior to the [3H]-2DG injection.Note: Alternatively, intravenous (IV) injection may be considered to reduce potential intra-group variability, which can result from inconsistencies in absorption or distribution associated with IP administration. Note: To activate brown and white adipose tissue, administer the CL316243 solution by IP injection at a dose of 1 μg per gram body weight 15 min prior to the [3H]-2DG injection. Note: Alternatively, intravenous (IV) injection may be considered to reduce potential intra-group variability, which can result from inconsistencies in absorption or distribution associated with IP administration. b.45 min after [3H]-2DG administration, euthanize the mouse and dissect tissues, including brown adipose tissue (BAT), inguinal white adipose tissue (iWAT), gonadal white adipose tissue (gWAT), skeletal muscle, kidney, heart, lung, and liver.Note: Stagger the injections by 15-min intervals to ensure that all mice are scarified at the same time point following [3H]-2DG administration (see Table 1). It is recommended that one person performs the injections while another person handles the sacrifices and tissue collections 45 min post-injection. 45 min after [3H]-2DG administration, euthanize the mouse and dissect tissues, including brown adipose tissue (BAT), inguinal white adipose tissue (iWAT), gonadal white adipose tissue (gWAT), skeletal muscle, kidney, heart, lung, and liver.Note: Stagger the injections by 15-min intervals to ensure that all mice are scarified at the same time point following [3H]-2DG administration (see Table 1). It is recommended that one person performs the injections while another person handles the sacrifices and tissue collections 45 min post-injection. Note: Stagger the injections by 15-min intervals to ensure that all mice are scarified at the same time point following [3H]-2DG administration (see Table 1). It is recommended that one person performs the injections while another person handles the sacrifices and tissue collections 45 min post-injection. 3.Processing of tissue samples to measure glucose uptake.a.Transfer each collected tissue (less than 100 mg) to a pre-weighed 1.5 mL safe-lock microcentrifuge tube.Pause point: The experiment can be paused after step 5. At this point, tissue samples may be snap-frozen on dry ice and stored at −80°C for later analysis.b.Determine the tissue weight by subtracting the pre-weighed tube weight from the total weight (tube + tissue).c.Add 10 volumes of 0.1 M NaOH to each tissue sample (e.g., 500 μL for 50 mg tissue sample).d.Incubate on a heat block at 96°C for 45 min to ensure complete tissue digestion. After digestion, neutralize by adding an equal volume of 0.1 M HCl (e.g., 500 μL) and mix vigorously.CRITICAL: Ensure that the safe-lock microcentrifuge tube is tightly closed to prevent leakage.e.Transfer 200 μL of the neutralized tissue homogenate into two separate microcentrifuge tubes, each containing the following:i.Add one aliquot to 800 μL of 4.6% perchloric acid and mix thoroughly.ii.Add another 200 μL aliquot to 400 μL of 0.3 M Ba(OH)2. Mix thoroughly and then neutralize by adding an equal volume of 0.3 M ZnSO4 (e.g., 400 μL).f.Centrifuge both the microcentrifuge tubes at 20,000 × g for 4 min at 4°C. After centrifugation, transfer 800 μL of the resulting supernatant into a 7 mL scintillation vial, which contains 5 mL of scintillation fluid, and vortex to mix well.Note: 2-deoxyglucose (2DG) is phosphorylated by hexokinase within the cell, being converted into 2-deoxyglucose-6-phosphate (2DG6P). This molecule is similar to glucose-6-phosphate but lacks the hydroxyl group at the 2-position, causing it to accumulate within the cell. The Ba2+ ions from Ba(OH)2 can bind to the phosphate group of 2DG6P, forming insoluble barium phosphate salts that precipitate out of solution (Figure 1B). This allows for selective measurement of intracellular 2DG6P, which reflects glucose phosphorylation activity.g.Measure the 3H radioactivity in both perchloric acid- and Ba(OH)2/ZnSO4-treated samples using a scintillation counter, counting each sample for 1 min to determine disintegrations per min (DPM). Processing of tissue samples to measure glucose uptake.a.Transfer each collected tissue (less than 100 mg) to a pre-weighed 1.5 mL safe-lock microcentrifuge tube.Pause point: The experiment can be paused after step 5. At this point, tissue samples may be snap-frozen on dry ice and stored at −80°C for later analysis.b.Determine the tissue weight by subtracting the pre-weighed tube weight from the total weight (tube + tissue).c.Add 10 volumes of 0.1 M NaOH to each tissue sample (e.g., 500 μL for 50 mg tissue sample).d.Incubate on a heat block at 96°C for 45 min to ensure complete tissue digestion. After digestion, neutralize by adding an equal volume of 0.1 M HCl (e.g., 500 μL) and mix vigorously.CRITICAL: Ensure that the safe-lock microcentrifuge tube is tightly closed to prevent leakage.e.Transfer 200 μL of the neutralized tissue homogenate into two separate microcentrifuge tubes, each containing the following:i.Add one aliquot to 800 μL of 4.6% perchloric acid and mix thoroughly.ii.Add another 200 μL aliquot to 400 μL of 0.3 M Ba(OH)2. Mix thoroughly and then neutralize by adding an equal volume of 0.3 M ZnSO4 (e.g., 400 μL).f.Centrifuge both the microcentrifuge tubes at 20,000 × g for 4 min at 4°C. After centrifugation, transfer 800 μL of the resulting supernatant into a 7 mL scintillation vial, which contains 5 mL of scintillation fluid, and vortex to mix well.Note: 2-deoxyglucose (2DG) is phosphorylated by hexokinase within the cell, being converted into 2-deoxyglucose-6-phosphate (2DG6P). This molecule is similar to glucose-6-phosphate but lacks the hydroxyl group at the 2-position, causing it to accumulate within the cell. The Ba2+ ions from Ba(OH)2 can bind to the phosphate group of 2DG6P, forming insoluble barium phosphate salts that precipitate out of solution (Figure 1B). This allows for selective measurement of intracellular 2DG6P, which reflects glucose phosphorylation activity.g.Measure the 3H radioactivity in both perchloric acid- and Ba(OH)2/ZnSO4-treated samples using a scintillation counter, counting each sample for 1 min to determine disintegrations per min (DPM). a.Transfer each collected tissue (less than 100 mg) to a pre-weighed 1.5 mL safe-lock microcentrifuge tube.Pause point: The experiment can be paused after step 5. At this point, tissue samples may be snap-frozen on dry ice and stored at −80°C for later analysis. Transfer each collected tissue (less than 100 mg) to a pre-weighed 1.5 mL safe-lock microcentrifuge tube.Pause point: The experiment can be paused after step 5. At this point, tissue samples may be snap-frozen on dry ice and stored at −80°C for later analysis. Pause point: The experiment can be paused after step 5. At this point, tissue samples may be snap-frozen on dry ice and stored at −80°C for later analysis. b.Determine the tissue weight by subtracting the pre-weighed tube weight from the total weight (tube + tissue). Determine the tissue weight by subtracting the pre-weighed tube weight from the total weight (tube + tissue). c.Add 10 volumes of 0.1 M NaOH to each tissue sample (e.g., 500 μL for 50 mg tissue sample). Add 10 volumes of 0.1 M NaOH to each tissue sample (e.g., 500 μL for 50 mg tissue sample). d.Incubate on a heat block at 96°C for 45 min to ensure complete tissue digestion. After digestion, neutralize by adding an equal volume of 0.1 M HCl (e.g., 500 μL) and mix vigorously.CRITICAL: Ensure that the safe-lock microcentrifuge tube is tightly closed to prevent leakage. Incubate on a heat block at 96°C for 45 min to ensure complete tissue digestion. After digestion, neutralize by adding an equal volume of 0.1 M HCl (e.g., 500 μL) and mix vigorously.CRITICAL: Ensure that the safe-lock microcentrifuge tube is tightly closed to prevent leakage. CRITICAL: Ensure that the safe-lock microcentrifuge tube is tightly closed to prevent leakage. e.Transfer 200 μL of the neutralized tissue homogenate into two separate microcentrifuge tubes, each containing the following:i.Add one aliquot to 800 μL of 4.6% perchloric acid and mix thoroughly.ii.Add another 200 μL aliquot to 400 μL of 0.3 M Ba(OH)2. Mix thoroughly and then neutralize by adding an equal volume of 0.3 M ZnSO4 (e.g., 400 μL). Transfer 200 μL of the neutralized tissue homogenate into two separate microcentrifuge tubes, each containing the following:i.Add one aliquot to 800 μL of 4.6% perchloric acid and mix thoroughly.ii.Add another 200 μL aliquot to 400 μL of 0.3 M Ba(OH)2. Mix thoroughly and then neutralize by adding an equal volume of 0.3 M ZnSO4 (e.g., 400 μL). i.Add one aliquot to 800 μL of 4.6% perchloric acid and mix thoroughly. Add one aliquot to 800 μL of 4.6% perchloric acid and mix thoroughly. ii.Add another 200 μL aliquot to 400 μL of 0.3 M Ba(OH)2. Mix thoroughly and then neutralize by adding an equal volume of 0.3 M ZnSO4 (e.g., 400 μL). Add another 200 μL aliquot to 400 μL of 0.3 M Ba(OH)2. Mix thoroughly and then neutralize by adding an equal volume of 0.3 M ZnSO4 (e.g., 400 μL). f.Centrifuge both the microcentrifuge tubes at 20,000 × g for 4 min at 4°C. After centrifugation, transfer 800 μL of the resulting supernatant into a 7 mL scintillation vial, which contains 5 mL of scintillation fluid, and vortex to mix well.Note: 2-deoxyglucose (2DG) is phosphorylated by hexokinase within the cell, being converted into 2-deoxyglucose-6-phosphate (2DG6P). This molecule is similar to glucose-6-phosphate but lacks the hydroxyl group at the 2-position, causing it to accumulate within the cell. The Ba2+ ions from Ba(OH)2 can bind to the phosphate group of 2DG6P, forming insoluble barium phosphate salts that precipitate out of solution (Figure 1B). This allows for selective measurement of intracellular 2DG6P, which reflects glucose phosphorylation activity. Centrifuge both the microcentrifuge tubes at 20,000 × g for 4 min at 4°C. After centrifugation, transfer 800 μL of the resulting supernatant into a 7 mL scintillation vial, which contains 5 mL of scintillation fluid, and vortex to mix well.Note: 2-deoxyglucose (2DG) is phosphorylated by hexokinase within the cell, being converted into 2-deoxyglucose-6-phosphate (2DG6P). This molecule is similar to glucose-6-phosphate but lacks the hydroxyl group at the 2-position, causing it to accumulate within the cell. The Ba2+ ions from Ba(OH)2 can bind to the phosphate group of 2DG6P, forming insoluble barium phosphate salts that precipitate out of solution (Figure 1B). This allows for selective measurement of intracellular 2DG6P, which reflects glucose phosphorylation activity. Note: 2-deoxyglucose (2DG) is phosphorylated by hexokinase within the cell, being converted into 2-deoxyglucose-6-phosphate (2DG6P). This molecule is similar to glucose-6-phosphate but lacks the hydroxyl group at the 2-position, causing it to accumulate within the cell. The Ba2+ ions from Ba(OH)2 can bind to the phosphate group of 2DG6P, forming insoluble barium phosphate salts that precipitate out of solution (Figure 1B). This allows for selective measurement of intracellular 2DG6P, which reflects glucose phosphorylation activity. g.Measure the 3H radioactivity in both perchloric acid- and Ba(OH)2/ZnSO4-treated samples using a scintillation counter, counting each sample for 1 min to determine disintegrations per min (DPM). Measure the 3H radioactivity in both perchloric acid- and Ba(OH)2/ZnSO4-treated samples using a scintillation counter, counting each sample for 1 min to determine disintegrations per min (DPM). 4.Data analysis.a.Subtract the DPM values of Ba(OH)2/ZnSO4-treated samples from those of perchloric acid-treated samples to determine the amount of [3H]-2DG6P (see Table S1). Refer to troubleshooting 3.Note: Both [3H]-2DG and [3H]-2DG6P are soluble in the perchloric acid, but only [3H]-2DG remains soluble after Ba(OH)2/ZnSO4 treatment. Therefore, the difference in DPM reflects the amount of intracellular [3H]-2DG6P.b.Determine DPM per milligram of tissue by dividing the measured DPM by the tissue amount (in mg) for each sample in perchloric acid- and Ba(OH)2/ZnSO4-treated aliquots.c.To convert DPM to the specific amount (pg) of [3H]-2DG taken up into the tissue in 45 min, the following calculation methods can be used.i.Convert specific activity to DPM per mole: 1 Ci is 2.22 × 1012 DPM. Given that [3H]-2DG supplied by PerkinElmer has a specific activity of 50 Ci/mmol, specific activity in DPM/mol = 50 Ci/mmol × 103 mmol/mol × 2.22 × 1012 DPM/Ci = 1.11 × 1017 DPM/mol.ii.Calculate moles of [3H]-2DG taken up: Moles = DPM measured/specific activity in DPM/mol.iii.Convert moles of [3H]-2DG to mass: Mass (mg) = Moles × 164.2 g/mol × 103 mg/g.Note: For example, if DPM measured is 10,000, the approximated amount (pg) of [3H]-2DG per mg tissue = 10,000 DPM/(1.11 × 1017 DPM/mol) × 164.2 g/mol × 1012 pg/g = 14.8 pgiv.Then, divide the amount (pg) of [3H]-2DG by tissue weight and time: 14.8 pg/100 mg/45 min = 3.3 × 10−3 pg/mg/min. Data analysis.a.Subtract the DPM values of Ba(OH)2/ZnSO4-treated samples from those of perchloric acid-treated samples to determine the amount of [3H]-2DG6P (see Table S1). Refer to troubleshooting 3.Note: Both [3H]-2DG and [3H]-2DG6P are soluble in the perchloric acid, but only [3H]-2DG remains soluble after Ba(OH)2/ZnSO4 treatment. Therefore, the difference in DPM reflects the amount of intracellular [3H]-2DG6P.b.Determine DPM per milligram of tissue by dividing the measured DPM by the tissue amount (in mg) for each sample in perchloric acid- and Ba(OH)2/ZnSO4-treated aliquots.c.To convert DPM to the specific amount (pg) of [3H]-2DG taken up into the tissue in 45 min, the following calculation methods can be used.i.Convert specific activity to DPM per mole: 1 Ci is 2.22 × 1012 DPM. Given that [3H]-2DG supplied by PerkinElmer has a specific activity of 50 Ci/mmol, specific activity in DPM/mol = 50 Ci/mmol × 103 mmol/mol × 2.22 × 1012 DPM/Ci = 1.11 × 1017 DPM/mol.ii.Calculate moles of [3H]-2DG taken up: Moles = DPM measured/specific activity in DPM/mol.iii.Convert moles of [3H]-2DG to mass: Mass (mg) = Moles × 164.2 g/mol × 103 mg/g.Note: For example, if DPM measured is 10,000, the approximated amount (pg) of [3H]-2DG per mg tissue = 10,000 DPM/(1.11 × 1017 DPM/mol) × 164.2 g/mol × 1012 pg/g = 14.8 pgiv.Then, divide the amount (pg) of [3H]-2DG by tissue weight and time: 14.8 pg/100 mg/45 min = 3.3 × 10−3 pg/mg/min. a.Subtract the DPM values of Ba(OH)2/ZnSO4-treated samples from those of perchloric acid-treated samples to determine the amount of [3H]-2DG6P (see Table S1). Refer to troubleshooting 3.Note: Both [3H]-2DG and [3H]-2DG6P are soluble in the perchloric acid, but only [3H]-2DG remains soluble after Ba(OH)2/ZnSO4 treatment. Therefore, the difference in DPM reflects the amount of intracellular [3H]-2DG6P. Subtract the DPM values of Ba(OH)2/ZnSO4-treated samples from those of perchloric acid-treated samples to determine the amount of [3H]-2DG6P (see Table S1). Refer to troubleshooting 3.Note: Both [3H]-2DG and [3H]-2DG6P are soluble in the perchloric acid, but only [3H]-2DG remains soluble after Ba(OH)2/ZnSO4 treatment. Therefore, the difference in DPM reflects the amount of intracellular [3H]-2DG6P. Note: Both [3H]-2DG and [3H]-2DG6P are soluble in the perchloric acid, but only [3H]-2DG remains soluble after Ba(OH)2/ZnSO4 treatment. Therefore, the difference in DPM reflects the amount of intracellular [3H]-2DG6P. b.Determine DPM per milligram of tissue by dividing the measured DPM by the tissue amount (in mg) for each sample in perchloric acid- and Ba(OH)2/ZnSO4-treated aliquots. Determine DPM per milligram of tissue by dividing the measured DPM by the tissue amount (in mg) for each sample in perchloric acid- and Ba(OH)2/ZnSO4-treated aliquots. c.To convert DPM to the specific amount (pg) of [3H]-2DG taken up into the tissue in 45 min, the following calculation methods can be used.i.Convert specific activity to DPM per mole: 1 Ci is 2.22 × 1012 DPM. Given that [3H]-2DG supplied by PerkinElmer has a specific activity of 50 Ci/mmol, specific activity in DPM/mol = 50 Ci/mmol × 103 mmol/mol × 2.22 × 1012 DPM/Ci = 1.11 × 1017 DPM/mol.ii.Calculate moles of [3H]-2DG taken up: Moles = DPM measured/specific activity in DPM/mol.iii.Convert moles of [3H]-2DG to mass: Mass (mg) = Moles × 164.2 g/mol × 103 mg/g.Note: For example, if DPM measured is 10,000, the approximated amount (pg) of [3H]-2DG per mg tissue = 10,000 DPM/(1.11 × 1017 DPM/mol) × 164.2 g/mol × 1012 pg/g = 14.8 pgiv.Then, divide the amount (pg) of [3H]-2DG by tissue weight and time: 14.8 pg/100 mg/45 min = 3.3 × 10−3 pg/mg/min. To convert DPM to the specific amount (pg) of [3H]-2DG taken up into the tissue in 45 min, the following calculation methods can be used.i.Convert specific activity to DPM per mole: 1 Ci is 2.22 × 1012 DPM. Given that [3H]-2DG supplied by PerkinElmer has a specific activity of 50 Ci/mmol, specific activity in DPM/mol = 50 Ci/mmol × 103 mmol/mol × 2.22 × 1012 DPM/Ci = 1.11 × 1017 DPM/mol.ii.Calculate moles of [3H]-2DG taken up: Moles = DPM measured/specific activity in DPM/mol.iii.Convert moles of [3H]-2DG to mass: Mass (mg) = Moles × 164.2 g/mol × 103 mg/g.Note: For example, if DPM measured is 10,000, the approximated amount (pg) of [3H]-2DG per mg tissue = 10,000 DPM/(1.11 × 1017 DPM/mol) × 164.2 g/mol × 1012 pg/g = 14.8 pgiv.Then, divide the amount (pg) of [3H]-2DG by tissue weight and time: 14.8 pg/100 mg/45 min = 3.3 × 10−3 pg/mg/min. i.Convert specific activity to DPM per mole: 1 Ci is 2.22 × 1012 DPM. Given that [3H]-2DG supplied by PerkinElmer has a specific activity of 50 Ci/mmol, specific activity in DPM/mol = 50 Ci/mmol × 103 mmol/mol × 2.22 × 1012 DPM/Ci = 1.11 × 1017 DPM/mol. Convert specific activity to DPM per mole: 1 Ci is 2.22 × 1012 DPM. Given that [3H]-2DG supplied by PerkinElmer has a specific activity of 50 Ci/mmol, specific activity in DPM/mol = 50 Ci/mmol × 103 mmol/mol × 2.22 × 1012 DPM/Ci = 1.11 × 1017 DPM/mol. ii.Calculate moles of [3H]-2DG taken up: Moles = DPM measured/specific activity in DPM/mol. Calculate moles of [3H]-2DG taken up: Moles = DPM measured/specific activity in DPM/mol. iii.Convert moles of [3H]-2DG to mass: Mass (mg) = Moles × 164.2 g/mol × 103 mg/g.Note: For example, if DPM measured is 10,000, the approximated amount (pg) of [3H]-2DG per mg tissue = 10,000 DPM/(1.11 × 1017 DPM/mol) × 164.2 g/mol × 1012 pg/g = 14.8 pg Convert moles of [3H]-2DG to mass: Mass (mg) = Moles × 164.2 g/mol × 103 mg/g.Note: For example, if DPM measured is 10,000, the approximated amount (pg) of [3H]-2DG per mg tissue = 10,000 DPM/(1.11 × 1017 DPM/mol) × 164.2 g/mol × 1012 pg/g = 14.8 pg Note: For example, if DPM measured is 10,000, the approximated amount (pg) of [3H]-2DG per mg tissue = 10,000 DPM/(1.11 × 1017 DPM/mol) × 164.2 g/mol × 1012 pg/g = 14.8 pg iv.Then, divide the amount (pg) of [3H]-2DG by tissue weight and time: 14.8 pg/100 mg/45 min = 3.3 × 10−3 pg/mg/min. Then, divide the amount (pg) of [3H]-2DG by tissue weight and time: 14.8 pg/100 mg/45 min = 3.3 × 10−3 pg/mg/min. 5.Clean-up and site monitoring.a.Dispose of used bedding and emptied Hydropacs into a double-bagged radioactive waste container in accordance with institutional radiation safety guidelines.b.Perform a wipe test inside the cages and on the food hoppers to check for radioactive contamination. Clean-up and site monitoring.a.Dispose of used bedding and emptied Hydropacs into a double-bagged radioactive waste container in accordance with institutional radiation safety guidelines.b.Perform a wipe test inside the cages and on the food hoppers to check for radioactive contamination. a.Dispose of used bedding and emptied Hydropacs into a double-bagged radioactive waste container in accordance with institutional radiation safety guidelines. Dispose of used bedding and emptied Hydropacs into a double-bagged radioactive waste container in accordance with institutional radiation safety guidelines. b.Perform a wipe test inside the cages and on the food hoppers to check for radioactive contamination. Perform a wipe test inside the cages and on the food hoppers to check for radioactive contamination. Note: If contamination is detected, decontaminate the surfaces using the appropriate decontamination solution before returning the cages to the animal facility. Note: During the 45-min administration of [3H]-2DG, no radioactive contamination was detected inside the cages. However, residual radioactivity was detected on the food hopper, particularly in the area that directly contacts the mouse’s injection site during scruffing. To minimize the risk of contamination, it is recommended to place protective barriers between the animal and any direct contact surfaces during post-injection handling. Table 1A timeline for in vivo [3H]-2DG administration and tissue harvestTime (min)00:0000:1500:3000:4500:6001:1501:3001:3001:45Mouse 1CL316243[3H]-2DGSTOPMouse 2CL316243[3H]-2DGSTOPMouse 3CL316243[3H]-2DGSTOPMouse 4CL316243[3H]-2DGSTOPMouse 5CL316243[3H]-2DGSTOPInjections are administered by 15-min intervals to ensure that all mice are scarified at the same time point following [3H]-2DG administration. A timeline for in vivo [3H]-2DG administration and tissue harvest Injections are administered by 15-min intervals to ensure that all mice are scarified at the same time point following [3H]-2DG administration. In vivo measurement of glucose uptake in brown adipose tissue (A) Schematic outline of in vivo glucose uptake assay. (B) The conversion of 2-deoxy-D-glucose to 2-deoxy-D-glucose-6-phosphate by hexokinase in glycolysis. Barium ions precipitate phosphate ions of 2-deoxy-D-[1,2-3H]glucose-6-phosphate to form insoluble barium phosphates, leaving the free 2-deoxy-D-[1,2–3H]glucose in solution for detection. (C) Glucose uptake in brown adipose tissue (BAT), inguinal white adipose tissue (iWAT), gonadal white adipose tissue (gWAT), skeletal muscle, kidney, heart, lung and liver was measured 45 min after I.P. injection of 2-deoxy-D-[1,2-3H]glucose (0.1 μCi/g body weight) under basal and CL316243-stimulated conditions. Glucose uptake is reported as disintegrations per min (DPM) per mg of wet tissue weight. Data are represented as mean. (D) Comparison of [3H] radioactive levels across the tissues 45 min after I.P. injection of two different doses of 2-deoxy-D-[1,2-3H]glucose under CL316243-stimulated conditions: 0.1 μCi/g body weight and 0.5 μCi/g body weight. Data are represented as mean ± SEM. (E and G) Tissue-specific glucose uptake per mg of tissue was measured 45 min after I.P. injection of 2-deoxy-D-[1,2-3H]glucose (0.5 μCi/g body weight) under CL316243-stimulated conditions. Glucose uptake is presented as the sum of 2-deoxy-D-[1,2-3H]glucose and its phosphorylated form 2-deoxy-D-[1,2-3H]glucose-6-phosphate. DPM per mg tissue in E was converted to the specific amount (pg) of glucose taken up into mg tissue in G. Data are represented as mean ± SEM. (F and H) Tissue-specific levels of 2-deoxy-D-[1,2-3H]glucose-6-phosphate corresponding to the data shown in E and G. Data are represented as mean ± SEM. Figures F and H are modified from the original Figure 3T published in Park et al. (2025).1 Ex vivo glucose uptake assay in freshly isolated brown adipose tissue Timing: 2–3 h This section describes the preparation of 2-deoxy-D-[1,2-3H]glucose solution and measurement of glucose uptake in freshly isolated brown adipose tissue (BAT). 6.Preparation of 2-deoxy-D-[1,2-3H]glucose solution.a.Turn on a shaking water bath and set it to 37°C.b.Prepare glucose-free Krebs-Ringer bicarbonate buffer (KRBB) composed of 117 mM NaCl, 4.7 mM KCl, 1.2 mM KH2PO4, 1.2 mM MgSO4, 25 mM NaHCO3, 2.5mM CaCl2, 20 mM HEPES, and 0.2% BSA.c.Place this buffer in the water bath and pre-warm until ready for use.d.Dissolve 2-deoxyglucose (2DG) in KRBB to make a 100 mM 2DG stock solution.e.Add an appropriate volume of 2-deoxy-D-[1,2-3H]glucose ([3H]-2DG) (stock radioactivity: 1 mCi/mL) and 100 mM 2DG stock solution to KRBB to make a 100× [3H]-2DG working solution containing 100 μCi/mL of [3H]-2DG and 20 mM of cold 2DG. Preparation of 2-deoxy-D-[1,2-3H]glucose solution.a.Turn on a shaking water bath and set it to 37°C.b.Prepare glucose-free Krebs-Ringer bicarbonate buffer (KRBB) composed of 117 mM NaCl, 4.7 mM KCl, 1.2 mM KH2PO4, 1.2 mM MgSO4, 25 mM NaHCO3, 2.5mM CaCl2, 20 mM HEPES, and 0.2% BSA.c.Place this buffer in the water bath and pre-warm until ready for use.d.Dissolve 2-deoxyglucose (2DG) in KRBB to make a 100 mM 2DG stock solution.e.Add an appropriate volume of 2-deoxy-D-[1,2-3H]glucose ([3H]-2DG) (stock radioactivity: 1 mCi/mL) and 100 mM 2DG stock solution to KRBB to make a 100× [3H]-2DG working solution containing 100 μCi/mL of [3H]-2DG and 20 mM of cold 2DG. a.Turn on a shaking water bath and set it to 37°C. Turn on a shaking water bath and set it to 37°C. b.Prepare glucose-free Krebs-Ringer bicarbonate buffer (KRBB) composed of 117 mM NaCl, 4.7 mM KCl, 1.2 mM KH2PO4, 1.2 mM MgSO4, 25 mM NaHCO3, 2.5mM CaCl2, 20 mM HEPES, and 0.2% BSA. Prepare glucose-free Krebs-Ringer bicarbonate buffer (KRBB) composed of 117 mM NaCl, 4.7 mM KCl, 1.2 mM KH2PO4, 1.2 mM MgSO4, 25 mM NaHCO3, 2.5mM CaCl2, 20 mM HEPES, and 0.2% BSA. c.Place this buffer in the water bath and pre-warm until ready for use. Place this buffer in the water bath and pre-warm until ready for use. d.Dissolve 2-deoxyglucose (2DG) in KRBB to make a 100 mM 2DG stock solution. Dissolve 2-deoxyglucose (2DG) in KRBB to make a 100 mM 2DG stock solution. e.Add an appropriate volume of 2-deoxy-D-[1,2-3H]glucose ([3H]-2DG) (stock radioactivity: 1 mCi/mL) and 100 mM 2DG stock solution to KRBB to make a 100× [3H]-2DG working solution containing 100 μCi/mL of [3H]-2DG and 20 mM of cold 2DG. Add an appropriate volume of 2-deoxy-D-[1,2-3H]glucose ([3H]-2DG) (stock radioactivity: 1 mCi/mL) and 100 mM 2DG stock solution to KRBB to make a 100× [3H]-2DG working solution containing 100 μCi/mL of [3H]-2DG and 20 mM of cold 2DG. Note: For example, add 10 μL of [3H]-2DG stock and 20 μL of 2DG stock to 70 μL of KRBB. CRITICAL: Personal protective equipment (PPE) must be worn while handling radioactive materials. Radioactive experiments must be carried out in the designated area. 7.Ex vivo glucose uptake assay in BAT.a.Rinse freshly isolated BAT several times with KRBB to remove blood and debris.b.Carefully cut the BAT in half and weigh each half separately using a precision analytical balance.c.Place each half of the BAT into a separate 14 mL round bottom tube containing 1 mL of pre-warmed KRBB.Note: Alternatively, each half of the BAT can be cut to four equal pieces and placed into a 14 mL tube containing 1 mL of pre-warmed KRBB.d.Place the tissue samples in a shaking water bath set to 37°C at 100 rpm for 5 min to allow the tissue to equilibrate in the buffer prior to the addition of the [3H]-2DG working solution.Note: To assess background or non-specific uptake of [3H]-2DG, add 0.2 mM cytochalasin B to the negative control during this step, adjusting the concentration to a final 20 μM.Note: Cytochalasin B inhibits glucose transporters (especially GLUT1), effectively blocking glucose transport across the plasma membrane.10e.Add 10 μL of the 100× [3H]-2DG working solution to each tube to achieve a final concentration of 1 μCi of [3H]-2DG and 0.2 mM of cold 2DG. Continue to incubate the tissue samples in a shaking water bath at 37°C for 15–20 min.f.To terminate glucose uptake, add 100 μL of 0.2 mM cytochalasin B to each tube. Immediately place the tubes on ice and incubate for 10 min to stop further transport activity.g.Transfer the tissue samples into a 12-well plate, placing one sample per well. Add 1 mL of ice-cold KRBB containing 5 μM of cytochalasin B to each well. Wash the tissue samples twice for 5 min.h.Add ice-cold KRBB without cytochalasin B and wash the tissue samples for 5 min.i.Transfer the tissue samples into 1.5 mL safe-lock microcentrifuge tubes. Carefully remove excess KRBB using a long pipette tip.j.Add 200 μL of 0.1 N NaOH to each tube and incubate on a heat block at 96°C for 45 min to ensure complete tissue digestion.k.After digestion, add an equal volume of 0.1 N HCl (e.g., 200 μL) to each tube to neutralize the solution, and mix vigorously.l.Centrifuge the tubes at 20,000 × g in a microcentrifuge for 10 min at 4°C.m.Transfer 300 μL of each tissue lysate into 4 mL of scintillation fluid in 7 mL scintillation vials.n.Measure the 3H radioactivity using a scintillation counter, counting each sample for 1 min to determine disintegrations per min (DPM).o.Subtract the DPM values of cytochalasin B-treated samples from those of untreated samples to determine the glucose transporter-mediated uptake.p.Determine DPM per milligram of tissue by dividing the measured DPM by the tissue amount (in mg) for each sample.CRITICAL: Dispose of used tubes, pipet tips, and buffers in designated radioactive solid and liquid waste containers, in accordance with institutional radiation safety guidelines. Ex vivo glucose uptake assay in BAT.a.Rinse freshly isolated BAT several times with KRBB to remove blood and debris.b.Carefully cut the BAT in half and weigh each half separately using a precision analytical balance.c.Place each half of the BAT into a separate 14 mL round bottom tube containing 1 mL of pre-warmed KRBB.Note: Alternatively, each half of the BAT can be cut to four equal pieces and placed into a 14 mL tube containing 1 mL of pre-warmed KRBB.d.Place the tissue samples in a shaking water bath set to 37°C at 100 rpm for 5 min to allow the tissue to equilibrate in the buffer prior to the addition of the [3H]-2DG working solution.Note: To assess background or non-specific uptake of [3H]-2DG, add 0.2 mM cytochalasin B to the negative control during this step, adjusting the concentration to a final 20 μM.Note: Cytochalasin B inhibits glucose transporters (especially GLUT1), effectively blocking glucose transport across the plasma membrane.10e.Add 10 μL of the 100× [3H]-2DG working solution to each tube to achieve a final concentration of 1 μCi of [3H]-2DG and 0.2 mM of cold 2DG. Continue to incubate the tissue samples in a shaking water bath at 37°C for 15–20 min.f.To terminate glucose uptake, add 100 μL of 0.2 mM cytochalasin B to each tube. Immediately place the tubes on ice and incubate for 10 min to stop further transport activity.g.Transfer the tissue samples into a 12-well plate, placing one sample per well. Add 1 mL of ice-cold KRBB containing 5 μM of cytochalasin B to each well. Wash the tissue samples twice for 5 min.h.Add ice-cold KRBB without cytochalasin B and wash the tissue samples for 5 min.i.Transfer the tissue samples into 1.5 mL safe-lock microcentrifuge tubes. Carefully remove excess KRBB using a long pipette tip.j.Add 200 μL of 0.1 N NaOH to each tube and incubate on a heat block at 96°C for 45 min to ensure complete tissue digestion.k.After digestion, add an equal volume of 0.1 N HCl (e.g., 200 μL) to each tube to neutralize the solution, and mix vigorously.l.Centrifuge the tubes at 20,000 × g in a microcentrifuge for 10 min at 4°C.m.Transfer 300 μL of each tissue lysate into 4 mL of scintillation fluid in 7 mL scintillation vials.n.Measure the 3H radioactivity using a scintillation counter, counting each sample for 1 min to determine disintegrations per min (DPM).o.Subtract the DPM values of cytochalasin B-treated samples from those of untreated samples to determine the glucose transporter-mediated uptake.p.Determine DPM per milligram of tissue by dividing the measured DPM by the tissue amount (in mg) for each sample.CRITICAL: Dispose of used tubes, pipet tips, and buffers in designated radioactive solid and liquid waste containers, in accordance with institutional radiation safety guidelines. a.Rinse freshly isolated BAT several times with KRBB to remove blood and debris. Rinse freshly isolated BAT several times with KRBB to remove blood and debris. b.Carefully cut the BAT in half and weigh each half separately using a precision analytical balance. Carefully cut the BAT in half and weigh each half separately using a precision analytical balance. c.Place each half of the BAT into a separate 14 mL round bottom tube containing 1 mL of pre-warmed KRBB.Note: Alternatively, each half of the BAT can be cut to four equal pieces and placed into a 14 mL tube containing 1 mL of pre-warmed KRBB. Place each half of the BAT into a separate 14 mL round bottom tube containing 1 mL of pre-warmed KRBB.Note: Alternatively, each half of the BAT can be cut to four equal pieces and placed into a 14 mL tube containing 1 mL of pre-warmed KRBB. Note: Alternatively, each half of the BAT can be cut to four equal pieces and placed into a 14 mL tube containing 1 mL of pre-warmed KRBB. d.Place the tissue samples in a shaking water bath set to 37°C at 100 rpm for 5 min to allow the tissue to equilibrate in the buffer prior to the addition of the [3H]-2DG working solution.Note: To assess background or non-specific uptake of [3H]-2DG, add 0.2 mM cytochalasin B to the negative control during this step, adjusting the concentration to a final 20 μM.Note: Cytochalasin B inhibits glucose transporters (especially GLUT1), effectively blocking glucose transport across the plasma membrane.10 Place the tissue samples in a shaking water bath set to 37°C at 100 rpm for 5 min to allow the tissue to equilibrate in the buffer prior to the addition of the [3H]-2DG working solution.Note: To assess background or non-specific uptake of [3H]-2DG, add 0.2 mM cytochalasin B to the negative control during this step, adjusting the concentration to a final 20 μM.Note: Cytochalasin B inhibits glucose transporters (especially GLUT1), effectively blocking glucose transport across the plasma membrane.10 Note: To assess background or non-specific uptake of [3H]-2DG, add 0.2 mM cytochalasin B to the negative control during this step, adjusting the concentration to a final 20 μM. Note: Cytochalasin B inhibits glucose transporters (especially GLUT1), effectively blocking glucose transport across the plasma membrane.10 e.Add 10 μL of the 100× [3H]-2DG working solution to each tube to achieve a final concentration of 1 μCi of [3H]-2DG and 0.2 mM of cold 2DG. Continue to incubate the tissue samples in a shaking water bath at 37°C for 15–20 min. Add 10 μL of the 100× [3H]-2DG working solution to each tube to achieve a final concentration of 1 μCi of [3H]-2DG and 0.2 mM of cold 2DG. Continue to incubate the tissue samples in a shaking water bath at 37°C for 15–20 min. f.To terminate glucose uptake, add 100 μL of 0.2 mM cytochalasin B to each tube. Immediately place the tubes on ice and incubate for 10 min to stop further transport activity. To terminate glucose uptake, add 100 μL of 0.2 mM cytochalasin B to each tube. Immediately place the tubes on ice and incubate for 10 min to stop further transport activity. g.Transfer the tissue samples into a 12-well plate, placing one sample per well. Add 1 mL of ice-cold KRBB containing 5 μM of cytochalasin B to each well. Wash the tissue samples twice for 5 min. Transfer the tissue samples into a 12-well plate, placing one sample per well. Add 1 mL of ice-cold KRBB containing 5 μM of cytochalasin B to each well. Wash the tissue samples twice for 5 min. h.Add ice-cold KRBB without cytochalasin B and wash the tissue samples for 5 min. Add ice-cold KRBB without cytochalasin B and wash the tissue samples for 5 min. i.Transfer the tissue samples into 1.5 mL safe-lock microcentrifuge tubes. Carefully remove excess KRBB using a long pipette tip. Transfer the tissue samples into 1.5 mL safe-lock microcentrifuge tubes. Carefully remove excess KRBB using a long pipette tip. j.Add 200 μL of 0.1 N NaOH to each tube and incubate on a heat block at 96°C for 45 min to ensure complete tissue digestion. Add 200 μL of 0.1 N NaOH to each tube and incubate on a heat block at 96°C for 45 min to ensure complete tissue digestion. k.After digestion, add an equal volume of 0.1 N HCl (e.g., 200 μL) to each tube to neutralize the solution, and mix vigorously. After digestion, add an equal volume of 0.1 N HCl (e.g., 200 μL) to each tube to neutralize the solution, and mix vigorously. l.Centrifuge the tubes at 20,000 × g in a microcentrifuge for 10 min at 4°C. Centrifuge the tubes at 20,000 × g in a microcentrifuge for 10 min at 4°C. m.Transfer 300 μL of each tissue lysate into 4 mL of scintillation fluid in 7 mL scintillation vials. Transfer 300 μL of each tissue lysate into 4 mL of scintillation fluid in 7 mL scintillation vials. n.Measure the 3H radioactivity using a scintillation counter, counting each sample for 1 min to determine disintegrations per min (DPM). Measure the 3H radioactivity using a scintillation counter, counting each sample for 1 min to determine disintegrations per min (DPM). o.Subtract the DPM values of cytochalasin B-treated samples from those of untreated samples to determine the glucose transporter-mediated uptake. Subtract the DPM values of cytochalasin B-treated samples from those of untreated samples to determine the glucose transporter-mediated uptake. p.Determine DPM per milligram of tissue by dividing the measured DPM by the tissue amount (in mg) for each sample.CRITICAL: Dispose of used tubes, pipet tips, and buffers in designated radioactive solid and liquid waste containers, in accordance with institutional radiation safety guidelines. Determine DPM per milligram of tissue by dividing the measured DPM by the tissue amount (in mg) for each sample.CRITICAL: Dispose of used tubes, pipet tips, and buffers in designated radioactive solid and liquid waste containers, in accordance with institutional radiation safety guidelines. CRITICAL: Dispose of used tubes, pipet tips, and buffers in designated radioactive solid and liquid waste containers, in accordance with institutional radiation safety guidelines. In vitro glucose uptake assay in cultured brown adipocytes Timing: 2–3 h This section describes the preparation of 2-deoxy-D-[1,2-3H]glucose solution and measurement of glucose uptake in fully differentiated brown adipocytes. 8.Preparation of 2-deoxy-D-[1,2-3H]glucose solution.a.Determine the total volume of 2-deoxy-D-[1,2-3H]glucose solution required for the experiment.Note: For example, the total volume required for a 12-well plate would be: 12× 500 μL/well = 6000 μL.b.Add an appropriate volume of 2-deoxy-D-[1,2-3H]glucose ([3H]-2DG) (stock radioactivity: 1 mCi/mL) and 100 mM 2DG stock to glucose-free DMEM at a final concentration of 1 μCi/mL of [3H]-2DG and 0.2 mM of cold 2DG.Note: Be sure to prepare extra volume beyond the calculated amount to account for any potential loss or error during handling.CRITICAL: Personal protective equipment (PPE) must be worn while handling radioactive materials. Radioactive experiments must be carried out in the designated area. Preparation of 2-deoxy-D-[1,2-3H]glucose solution.a.Determine the total volume of 2-deoxy-D-[1,2-3H]glucose solution required for the experiment.Note: For example, the total volume required for a 12-well plate would be: 12× 500 μL/well = 6000 μL.b.Add an appropriate volume of 2-deoxy-D-[1,2-3H]glucose ([3H]-2DG) (stock radioactivity: 1 mCi/mL) and 100 mM 2DG stock to glucose-free DMEM at a final concentration of 1 μCi/mL of [3H]-2DG and 0.2 mM of cold 2DG.Note: Be sure to prepare extra volume beyond the calculated amount to account for any potential loss or error during handling.CRITICAL: Personal protective equipment (PPE) must be worn while handling radioactive materials. Radioactive experiments must be carried out in the designated area. a.Determine the total volume of 2-deoxy-D-[1,2-3H]glucose solution required for the experiment.Note: For example, the total volume required for a 12-well plate would be: 12× 500 μL/well = 6000 μL. Determine the total volume of 2-deoxy-D-[1,2-3H]glucose solution required for the experiment.Note: For example, the total volume required for a 12-well plate would be: 12× 500 μL/well = 6000 μL. Note: For example, the total volume required for a 12-well plate would be: 12× 500 μL/well = 6000 μL. b.Add an appropriate volume of 2-deoxy-D-[1,2-3H]glucose ([3H]-2DG) (stock radioactivity: 1 mCi/mL) and 100 mM 2DG stock to glucose-free DMEM at a final concentration of 1 μCi/mL of [3H]-2DG and 0.2 mM of cold 2DG.Note: Be sure to prepare extra volume beyond the calculated amount to account for any potential loss or error during handling.CRITICAL: Personal protective equipment (PPE) must be worn while handling radioactive materials. Radioactive experiments must be carried out in the designated area. Add an appropriate volume of 2-deoxy-D-[1,2-3H]glucose ([3H]-2DG) (stock radioactivity: 1 mCi/mL) and 100 mM 2DG stock to glucose-free DMEM at a final concentration of 1 μCi/mL of [3H]-2DG and 0.2 mM of cold 2DG.Note: Be sure to prepare extra volume beyond the calculated amount to account for any potential loss or error during handling.CRITICAL: Personal protective equipment (PPE) must be worn while handling radioactive materials. Radioactive experiments must be carried out in the designated area. Note: Be sure to prepare extra volume beyond the calculated amount to account for any potential loss or error during handling. CRITICAL: Personal protective equipment (PPE) must be worn while handling radioactive materials. Radioactive experiments must be carried out in the designated area. 9.In vitro glucose uptake assay in brown adipocytes.a.Gently rinse brown adipocytes twice with pre-warmed 1× PBS, taking care to avoid dislodging the cells during this process.b.Add 500 μL of pre-warmed [3H]-2DG glucose solution per well and incubate at 37°C for 10 min.Note: To assess background or non-specific uptake of [3H]-2DG, add 0.2 mM cytochalasin B to the negative control during this step, adjusting the concentration to a final 20 μM.c.Terminate the glucose uptake by adding 50 μL of 0.2 mM Cytochalasin B to each well and rinse the cells three times with ice-cold 1× PBS.d.Add 200 μL of 0.1 N NaOH to each well to detach and lyse the cells. Transfer the resulting cell suspension into 1.5 mL safe-lock microcentrifuge tubes.e.Incubate on a heat block at 96°C for 45 min to ensure complete digestion.f.After digestion, add an equal volume of 0.1 N HCl (e.g., 200 μL) to each tube to neutralize the solution, and mix vigorously.g.Centrifuge at 20,000 × g in a microcentrifuge for 10 min at 4°C.h.Transfer 300 μL of each cell lysate into 4 mL of scintillation fluid in 7 mL scintillation vials.Note: Take a small aliquot from each cell lysate sample to quantify protein concentration, using a standard assay such as BCA or Bradford.i.Measure the 3H radioactivity using a scintillation counter, counting each sample for 1 min to determine disintegrations per min (DPM).j.Subtract the DPM values of cytochalasin B-treated cells from those of untreated cells to determine the glucose transporter-mediated uptake. In vitro glucose uptake assay in brown adipocytes.a.Gently rinse brown adipocytes twice with pre-warmed 1× PBS, taking care to avoid dislodging the cells during this process.b.Add 500 μL of pre-warmed [3H]-2DG glucose solution per well and incubate at 37°C for 10 min.Note: To assess background or non-specific uptake of [3H]-2DG, add 0.2 mM cytochalasin B to the negative control during this step, adjusting the concentration to a final 20 μM.c.Terminate the glucose uptake by adding 50 μL of 0.2 mM Cytochalasin B to each well and rinse the cells three times with ice-cold 1× PBS.d.Add 200 μL of 0.1 N NaOH to each well to detach and lyse the cells. Transfer the resulting cell suspension into 1.5 mL safe-lock microcentrifuge tubes.e.Incubate on a heat block at 96°C for 45 min to ensure complete digestion.f.After digestion, add an equal volume of 0.1 N HCl (e.g., 200 μL) to each tube to neutralize the solution, and mix vigorously.g.Centrifuge at 20,000 × g in a microcentrifuge for 10 min at 4°C.h.Transfer 300 μL of each cell lysate into 4 mL of scintillation fluid in 7 mL scintillation vials.Note: Take a small aliquot from each cell lysate sample to quantify protein concentration, using a standard assay such as BCA or Bradford.i.Measure the 3H radioactivity using a scintillation counter, counting each sample for 1 min to determine disintegrations per min (DPM).j.Subtract the DPM values of cytochalasin B-treated cells from those of untreated cells to determine the glucose transporter-mediated uptake. a.Gently rinse brown adipocytes twice with pre-warmed 1× PBS, taking care to avoid dislodging the cells during this process. Gently rinse brown adipocytes twice with pre-warmed 1× PBS, taking care to avoid dislodging the cells during this process. b.Add 500 μL of pre-warmed [3H]-2DG glucose solution per well and incubate at 37°C for 10 min.Note: To assess background or non-specific uptake of [3H]-2DG, add 0.2 mM cytochalasin B to the negative control during this step, adjusting the concentration to a final 20 μM. Add 500 μL of pre-warmed [3H]-2DG glucose solution per well and incubate at 37°C for 10 min.Note: To assess background or non-specific uptake of [3H]-2DG, add 0.2 mM cytochalasin B to the negative control during this step, adjusting the concentration to a final 20 μM. Note: To assess background or non-specific uptake of [3H]-2DG, add 0.2 mM cytochalasin B to the negative control during this step, adjusting the concentration to a final 20 μM. c.Terminate the glucose uptake by adding 50 μL of 0.2 mM Cytochalasin B to each well and rinse the cells three times with ice-cold 1× PBS. Terminate the glucose uptake by adding 50 μL of 0.2 mM Cytochalasin B to each well and rinse the cells three times with ice-cold 1× PBS. d.Add 200 μL of 0.1 N NaOH to each well to detach and lyse the cells. Transfer the resulting cell suspension into 1.5 mL safe-lock microcentrifuge tubes. Add 200 μL of 0.1 N NaOH to each well to detach and lyse the cells. Transfer the resulting cell suspension into 1.5 mL safe-lock microcentrifuge tubes. e.Incubate on a heat block at 96°C for 45 min to ensure complete digestion. Incubate on a heat block at 96°C for 45 min to ensure complete digestion. f.After digestion, add an equal volume of 0.1 N HCl (e.g., 200 μL) to each tube to neutralize the solution, and mix vigorously. After digestion, add an equal volume of 0.1 N HCl (e.g., 200 μL) to each tube to neutralize the solution, and mix vigorously. g.Centrifuge at 20,000 × g in a microcentrifuge for 10 min at 4°C. Centrifuge at 20,000 × g in a microcentrifuge for 10 min at 4°C. h.Transfer 300 μL of each cell lysate into 4 mL of scintillation fluid in 7 mL scintillation vials.Note: Take a small aliquot from each cell lysate sample to quantify protein concentration, using a standard assay such as BCA or Bradford. Transfer 300 μL of each cell lysate into 4 mL of scintillation fluid in 7 mL scintillation vials.Note: Take a small aliquot from each cell lysate sample to quantify protein concentration, using a standard assay such as BCA or Bradford. Note: Take a small aliquot from each cell lysate sample to quantify protein concentration, using a standard assay such as BCA or Bradford. i.Measure the 3H radioactivity using a scintillation counter, counting each sample for 1 min to determine disintegrations per min (DPM). Measure the 3H radioactivity using a scintillation counter, counting each sample for 1 min to determine disintegrations per min (DPM). j.Subtract the DPM values of cytochalasin B-treated cells from those of untreated cells to determine the glucose transporter-mediated uptake. Subtract the DPM values of cytochalasin B-treated cells from those of untreated cells to determine the glucose transporter-mediated uptake. 10.Determine DPM per milligram of protein by dividing the measured DPM by the total protein amount (in mg) for each sample. Determine DPM per milligram of protein by dividing the measured DPM by the total protein amount (in mg) for each sample. CRITICAL: Dispose of used tubes, pipet tips, and buffers in designated radioactive solid and liquid waste containers, in accordance with institutional radiation safety guidelines. Expected outcomes A successful in vivo glucose uptake assay should demonstrate tissue-specific [3H]-2DG uptake that correlates with the metabolic activity of each tissue under the given experimental conditions. An example of this is shown in Figure 1C, where administration of the β3-adrenergic receptor (β3-AR) agonist CL316243 selectively increased [3H]-2DG uptake in brown adipose tissue (BAT). BAT exhibited the highest [3H]-2DG uptake among all tissues examined (Figure 1C). Elevated [3H] signal detected in the heart may, in part, reflect residual circulating [3H]-2DG in the bloodstream rather than true tissue-specific uptake. Furthermore, increasing the tracer dose fivefold resulted in a proportionally elevated uptake in BAT and other tissues (Figure 1D). Notably, the elevated [3H]-2DG uptake in BAT was closely associated with increased accumulation of [3H]-2DG-6-phosphate (Figures 1E–1H), suggesting enhanced glycolytic flux in this tissue under β3AR-stimulated conditions. Similarly, successful ex vivo and in vitro glucose uptake assays should demonstrate transporter-specific uptake across the plasma membrane. This is illustrated in Figures 2 and 3, which show specific glucose uptake in freshly isolated BAT and cultured brown adipocytes, respectively. Transporter-mediated glucose entry can be quantified by subtracting non-specific uptake −measured in the presence of cytochalasin B− from total uptake (Figures 2B and 3B). Subsequent normalization to tissue weight or protein content should be carried out for accurate comparisons between experimental groups. Consistent with the in vivo findings, β-adrenergic stimulation of brown adipocytes with isoproterenol significantly enhanced [3H]-2DG uptake (Figure 3C), further validating the assay’s sensitivity to metabolic activation. Ex vivo measurement of glucose uptake in brown adipose tissue (A) Schematic outline of ex vivo glucose uptake assay. (B) Glucose uptake per mg of BAT was measured 20 min after addition of 1 μCi of 2-deoxy-D-[1,2-3H]glucose, in the presence or absence of cytochalasin (B). Freshly isolated BAT was divided into two: one half was treated as an intact tissue, while the other was cut into four pieces prior to treatment. Data are represented as mean ± SEM. In vitro measurement of glucose uptake in cultured brown adipocytes (A) Schematic outline of in vitro glucose uptake assay. (B) Glucose uptake in fully differentiated brown adipocytes was measured 10 min after addition of 1 μCi of 2-deoxy-D-[1,2-3H]glucose in the presence or absence of cytochalasin B. Data are represented as mean ± SEM, ∗∗∗∗P < 0.0001. (C) Glucose uptake in fully differentiated brown adipocytes was measured 10 min after addition of 1 μCi of 2-deoxy-D-[1,2-3H]glucose under basal and isoproterenol (ISO)-stimulated conditions. Data are represented as mean ± SEM, ∗∗∗P < 0.001. Quantification and statistical analysis The data were analyzed and visualized using GraphPad Prism 10 software (Dotmatics, Boston, MA). Differences between two groups were evaluated using the unpaired two-tailed Student’s t test or two-way ANOVA with Bonferroni’s multiple comparisons as post-test. Data were presented as means ± SEM, with statistical significance set at p < 0.05. Significance is considered as ∗∗∗p < 0.001, ∗∗∗∗p < 0.0001. Limitations This protocol is optimized to assess both glucose uptake and phosphorylation in brown adipose tissue, which is characterized by inherently high metabolic activity. However, quantifying glucose phosphorylation in other tissues is challenging due to the low levels of detectable [3H]-2DG-6-phosphate and substantial inter-individual variability. These factors can significantly compromise the accuracy and reliability of glucose phosphorylation measurements in non-BAT tissues under the conditions tested. Another limitation of the in vivo glucose uptake assay is the lack of control for non-specific [3H]-2DG binding. In contrast, ex vivo and in vitro glucose uptake assays incorporate cytochalasin B to define and subtract non-specific uptake, thereby enhancing the specificity of the measurement. Troubleshooting Problem 1 There are large biological variations in tissue-specific glucose uptake between animals (related to Mouse Preparation Step 1). Potential solution Ensure that each experimental group includes enough animals to achieve statistical reliability. Also, ensure that animals in each experimental group are matched for age, sex, diet, and housing conditions. Problem 2 Cells tend to accumulate at the center of the well shortly after plating, especially in the incubator (related to Brown Adipocyte Preparation Step 1). Potential solution If this occurs within a few minutes, gently shake the plate back and forth and side to side several times to redistribute the cells evenly. The more cells are seeded, the higher tendency cells are concentrated at the center. Seed the cells at the density of 3 × 104 cells per well (cell growth area per well is 3.8 cm2) in a 12-well plate. Problem 3 Brown adipocyte differentiation is inconsistent across the wells (related to Brown Adipocyte Preparation Steps 1 and 2). Potential solution Seed cells evenly at approximately 30% confluence and allow them to grow until they reach 90%–100% confluence before initiating differentiation. Uniform cell distribution is critical for achieving consistent and complete differentiation efficiency. Problem 4 There are large technical variations in tissue-specific glucose uptake (related to Method Step 2a). Potential solution Administer [3H]-2DG in a sufficiently large volume, ensuring a minimum of 100 μL per animal during intraperitoneal (IP) injection. Alternatively, intravenous (IV) injection may be considered to reduce potential intra-group variability, which can result from inconsistencies in absorption or distribution associated with IP administration. Problem 5 The amount of [3H]-2DG-6-phosphate in tissue samples is significantly lower than that of [3H]-2DG and varies across different tissues (related to Method Step 3f). Potential solution Consider increasing the dose of the [3H]-2DG tracer to enhance detection sensitivity and reduce the impact of individual variability. Resource availability Lead contact Further information and requests for resources and reagents should be directed to and will be fulfilled by the lead contact, Ji Suk Chang (jisuk.chang@pbrc.edu). Technical contact Technical questions on executing this protocol should be directed to and will be answered by the technical contact, Ji Suk Chang (jisuk.chang@pbrc.edu). Materials availability This study did not generate new materials. Data and code availability The data reported in this study are shared by the lead contact upon request. This study does not report original code. Any additional information required to reanalyze the data reported in this study is available from the lead contact upon request. Acknowledgments This work was supported by the National Institutes of Health grant R01DK136536 (J.S.C.) and used Cell Biology & Bioimaging Core and Animal Core that are supported in part by COBRE (1P20GM135002-01) and NORC (P30DK072476) center grants from the National Institutes of Health. Author contributions C.-H.P. conducted the experiments and analyzed the data. J.S.C. conceived of the presented idea and wrote the manuscript. Declaration of interests The authors declare no competing interests. Footnotes Supplemental information can be found online at https://doi.org/10.1016/j.xpro.2025.104244. Supplemental information Table S1. A spreadsheet for quantification of radiolabeled glucose uptake and utilization, related to Step 4 References Associated Data Supplementary Materials Table S1. A spreadsheet for quantification of radiolabeled glucose uptake and utilization, related to Step 4 Data Availability Statement The data reported in this study are shared by the lead contact upon request. This study does not report original code. Any additional information required to reanalyze the data reported in this study is available from the lead contact upon request.